🚀 VC round data is live in beta, check it out!
vTv Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for vTv Therapeutics and similar public comparables like Fate Therapeutics, Ryvu Therapeutics, Black Diamond Therapeutics, Mersana Therapeutics and more.
vTv Therapeutics Overview
About vTv Therapeutics
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
Founded
2015
HQ
Employees
23
Website
Sectors
Financials (LTM)
EV
$49M
vTv Therapeutics Financials
vTv Therapeutics reported last 12-month revenue of $4M.
In the same LTM period, vTv Therapeutics generated $4M in gross profit and had net loss of ($28M).
Revenue (LTM)
vTv Therapeutics P&L
In the most recent fiscal year, vTv Therapeutics reported revenue of — and EBITDA of ($31M).
vTv Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $4M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($31M) | XXX | XXX | XXX |
| EBIT Margin | (913%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($28M) | XXX | ($27M) | XXX | XXX | XXX |
| Net Margin | (772%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
vTv Therapeutics Stock Performance
vTv Therapeutics has current market cap of $147M, and enterprise value of $49M.
Market Cap Evolution
vTv Therapeutics' stock price is $37.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $49M | $147M | -2.6% | XXX | XXX | XXX | $-6.85 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialvTv Therapeutics Valuation Multiples
vTv Therapeutics trades at 13.4x EV/Revenue multiple, and (1.6x) EV/EBITDA.
EV / Revenue (LTM)
vTv Therapeutics Financial Valuation Multiples
As of April 11, 2026, vTv Therapeutics has market cap of $147M and EV of $49M.
Equity research analysts estimate vTv Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
vTv Therapeutics has a P/E ratio of (5.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $147M | XXX | $147M | XXX | XXX | XXX |
| EV (current) | $49M | XXX | $49M | XXX | XXX | XXX |
| EV/Revenue | 13.4x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.6x) | XXX | XXX | XXX |
| EV/EBIT | (1.5x) | XXX | (1.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 13.4x | XXX | — | XXX | XXX | XXX |
| P/E | (5.2x) | XXX | (5.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified vTv Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
vTv Therapeutics Margins & Growth Rates
vTv Therapeutics' revenue in the last 12 month grew by 171%.
vTv Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.4M for the same period.
vTv Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 171% | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 38% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.4M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 438% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 584% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
vTv Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Fate Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ryvu Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Black Diamond Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mersana Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Genetic Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
vTv Therapeutics M&A Activity
vTv Therapeutics acquired XXX companies to date.
Last acquisition by vTv Therapeutics was on XXXXXXXX, XXXXX. vTv Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by vTv Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialvTv Therapeutics Investment Activity
vTv Therapeutics invested in XXX companies to date.
vTv Therapeutics made its latest investment on XXXXXXXX, XXXXX. vTv Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by vTv Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout vTv Therapeutics
| When was vTv Therapeutics founded? | vTv Therapeutics was founded in 2015. |
| Where is vTv Therapeutics headquartered? | vTv Therapeutics is headquartered in United States. |
| How many employees does vTv Therapeutics have? | As of today, vTv Therapeutics has over 23 employees. |
| Who is the CEO of vTv Therapeutics? | vTv Therapeutics' CEO is Paul J. Sekhri. |
| Is vTv Therapeutics publicly listed? | Yes, vTv Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of vTv Therapeutics? | vTv Therapeutics trades under VTVT ticker. |
| When did vTv Therapeutics go public? | vTv Therapeutics went public in 2015. |
| Who are competitors of vTv Therapeutics? | vTv Therapeutics main competitors are Fate Therapeutics, Ryvu Therapeutics, Black Diamond Therapeutics, Mersana Therapeutics. |
| What is the current market cap of vTv Therapeutics? | vTv Therapeutics' current market cap is $147M. |
| What is the current revenue of vTv Therapeutics? | vTv Therapeutics' last 12 months revenue is $4M. |
| What is the current revenue growth of vTv Therapeutics? | vTv Therapeutics revenue growth (NTM/LTM) is 171%. |
| What is the current EV/Revenue multiple of vTv Therapeutics? | Current revenue multiple of vTv Therapeutics is 13.4x. |
| Is vTv Therapeutics profitable? | No, vTv Therapeutics is not profitable. |
| What is the current net income of vTv Therapeutics? | vTv Therapeutics' last 12 months net income is ($28M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.